Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies

NCT02293941 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped Completed stage I without pursuing stage II

Conditions

Chronic Hepatitis C

Interventions

DRUG: JKB-122 5mg
DRUG: JKB-122 15mg
DRUG: JKB-122 35mg
DRUG: Placebo

Sponsor

TaiwanJ Pharmaceuticals Co., Ltd